
Codiak BioSciences CDAK
Codiak BioSciences Abschreibung & Amortisation | CDAK
Abschreibung & Amortisation Jährlich Codiak BioSciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.34 M | 4.36 M | 2.8 M | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 5.34 M | 2.8 M | 4.17 M |
Abschreibung & Amortisation Vierteljährlich Codiak BioSciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 3.18 M | 2.13 M | 1.08 M | - | 1.4 M | 1.4 M | 1.39 M | - | 1.1 M | 900 K | 1.03 M | - | 800 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 3.18 M | 800 K | 1.44 M |
Abschreibung & Amortisation anderer Aktien in der Pharmaeinzelhändler
| Name | Abschreibung & Amortisation | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Repare Therapeutics
RPTX
|
1.92 M | - | - | $ 112 M | ||
|
Sesen Bio
SESN
|
3.35 M | - | 7.29 % | $ 127 M | ||
|
Windtree Therapeutics
WINT
|
84 K | - | - | $ 26.8 M | ||
|
Trean Insurance Group
TIG
|
820 K | - | - | $ 316 M | ||
|
SQZ Biotechnologies Company
SQZ
|
1.5 M | - | 57.95 % | $ 12.8 M | ||
|
MEI Pharma
MEIP
|
368 K | - | 10.43 % | $ 20.5 M | ||
|
Palatin Technologies
PTN
|
62.7 K | - | - | $ 13 M | ||
|
Lyra Therapeutics
LYRA
|
459 K | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | ||
|
Generation Bio Co.
GBIO
|
4.93 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-339 K | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
2.29 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
1.2 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
2.17 M | $ 4.2 | -0.36 % | $ 651 M | ||
|
AbbVie
ABBV
|
762 M | $ 294.72 | 0.32 % | $ 521 B | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
83 K | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
228 K | $ 6.78 | 0.89 % | $ 296 M | ||
|
Axon Enterprise
AXON
|
83.2 M | $ 316.97 | 4.77 % | $ 24.7 B | ||
|
TFF Pharmaceuticals
TFFP
|
502 K | - | -60.05 % | $ 125 K | ||
|
Bristol-Myers Squibb Company
BMY
|
4.01 B | $ 62.89 | 0.18 % | $ 128 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
10.8 M | - | -15.15 % | $ 60.3 M | ||
|
Axcella Health
AXLA
|
412 K | - | -16.42 % | $ 249 M | ||
|
Cytokinetics, Incorporated
CYTK
|
10.1 M | $ 58.59 | 4.29 % | $ 7.04 M | ||
|
Dynavax Technologies Corporation
DVAX
|
4.63 M | - | - | $ 2.02 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 159.75 | 5.35 % | $ 20.9 B | ||
|
Amgen
AMGN
|
5.17 B | $ 467.97 | 0.59 % | $ 252 B | ||
|
Orgenesis
ORGS
|
2.09 M | - | -33.86 % | $ 61.2 M | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
41.6 M | $ 248.31 | 1.17 % | $ 15.1 B | ||
|
Johnson & Johnson
JNJ
|
7.5 B | $ 280.31 | -0.17 % | $ 675 B | ||
|
Kala Pharmaceuticals
KALA
|
317 K | $ 0.17 | 0.64 % | $ 1.39 M | ||
|
Sage Therapeutics
SAGE
|
1.03 M | - | - | $ 527 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 1.59 | -2.76 % | $ 2.62 M | ||
|
Lineage Cell Therapeutics
LCTX
|
699 K | $ 1.13 | 8.17 % | $ 260 M | ||
|
Paratek Pharmaceuticals
PRTK
|
490 K | - | - | $ 121 M | ||
|
TCR2 Therapeutics
TCRR
|
3.05 M | - | - | $ 58.1 M | ||
|
C4 Therapeutics
CCCC
|
1.96 M | $ 2.9 | -3.5 % | $ 240 M | ||
|
Eli Lilly and Company
LLY
|
2 B | $ 1 437.4 | 0.36 % | $ 1.29 T | ||
|
Compugen Ltd.
CGEN
|
475 K | $ 2.09 | -0.24 % | $ 195 M | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
3.9 M | $ 84.95 | 0.13 % | $ 7.99 B |